Work

Biomarkers for cystic fibrosis drug development

Year: 2016

Type: article

Source: Journal of Cystic Fibrosis

DOI: 10.1016/j.jcf.2016.10.009

Authors: Marianne S. Muhlebach, JP Clancy, Sonya L. Heltshe, Assem Ziady, Tom Kelley, Frank Accurso, Joseph Pilewski, Nicole Mayer-Hamblett, Elizabeth Joseloff, Scott D. Sagel

Institutions: University of North Carolina at Chapel Hill, Cincinnati Children's Hospital Medical Center, University of Washington, Children's Hospital Colorado, University of Colorado Anschutz, University of Pittsburgh, Case Western Reserve University, Cystic Fibrosis Foundation

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Cystic Fibrosis Foundation, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: G1342907914, G2296301935, G308544354, Mucus and hypoxia in heterogeneous and progressive CF lung disease, G3991547501, G9000144677, G9000261293, Center for Cystic Fibrosis Translational Research in the Post-CFTR modulator Era

OpenAlex ID: W2542408568

FWCI: 6.616

Cites: 122

Cited by: 68

Related to: 10